Early data on NextCure's immuno-oncology drug in lung cancer patients delights investors
Shares of freshly public biotech NextCure skyrocketed on Tuesday after the company published an abstract highlighting initial data from an early-stage study of its sole experimental immuno-oncology drug.
The therapy, NC318, is engineered to inhibit Siglec-15 (S15), a key immune suppressor in certain cancer patients whose tumors are resistant to the existing raft of checkpoint inhibitors. S15 is found on certain myeloid cells in the tumor microenvironment and on certain tumor types including lung, ovarian and head, and neck cancers.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.